P11.57.B OVER ONE YEAR OF SURVIVAL DIFFERENCE BETWEEN DISTINCT COHORTS OF GLIOBLASTOMA PATIENTS

Abstract

Abstract BACKGROUND Understanding the differences in outcomes based on study and patient characteristics can inform better research designs and improve the interpretation of translational glioblastoma studies. MATERIAL AND METHODS This study compared the clinical features and median overall survival (mOS) of 2,203 patients from two genomic cohorts (The Cancer Genome Atlas [TCGA] and the Chinese Glioma Genome Atlas [CGGA]) and two consecutive regional cohorts (Hong Kong [HK] and Southeast [SE] Scotland) with histologically confirmed glioblastoma. RESULTS A total of 2,203 patients with newly diagnosed glioblastoma were identified, including 414 from SE Scotland, 1,033 from HK, 510 from TCGA, and 246 from CGGA. In patients who have available treatment data and received standard chemoradiotherapy, the mOS was 35.2 months (95%CI 27.1-50.2) in SE Scotland, 22.2 (95%CI 19.0-25.5) in HK, and 14.1 months (95%CI 11.8-17.9) in TCGA. Using data from 1,023 patients from SE Scotland (N=414) and HK (N=609) where sufficient data was available, the multivariable Cox regression model did not demonstrate survival differences among patients treated in HK compared to those treated in SE Scotland (hazard ratio 0.93; 95%CI 0.80-1.08; p=0.30). CONCLUSION Survival differences between distinct cohorts of glioblastoma patients warrant further investigations into associated determinants to assess reproducibility and generalizability of research.